TL;DR: Aetna, a CVS Health company, modified CPB 0618 governing BNP testing coverage, effective January 29, 2026. CPT 83880 is the primary code affected — and the line between covered and denied is narrow.
Aetna's brain natriuretic peptide (BNP) testing coverage policy under CPB 0618 in the Aetna system draws a sharp line between medically necessary testing and experimental use. If your team bills CPT 83880 for natriuretic peptide testing, this update matters. The policy defines exactly five covered indications — and lists more than 30 uses it considers experimental, investigational, or unproven. One wrong diagnosis code pairing and you're looking at a claim denial.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Brain Natriuretic Peptide Testing |
| Policy Code | CPB 0618 |
| Change Type | Modified |
| Effective Date | January 29, 2026 |
| Impact Level | High |
| Specialties Affected | Cardiology, Internal Medicine, Nephrology, Oncology, Endocrinology, Hospital Medicine |
| Key Action | Audit all CPT 83880 claims to confirm ICD-10 pairing matches one of five covered indications before January 29, 2026 |
Aetna BNP Testing Coverage Criteria and Medical Necessity Requirements 2026
Aetna's BNP testing coverage policy under CPB 0618 covers CPT 83880 for natriuretic peptide measurement in five specific situations. These are the only scenarios where Aetna considers testing medically necessary.
The five covered indications are:
| # | Covered Indication |
|---|---|
| 1 | Differentiating dyspnea caused by heart failure from dyspnea caused by pulmonary disease |
| 2 | Determining prognosis or disease severity in chronic heart failure |
| 3 | Determining risk of developing heart failure in patients with risk factors — including cardiovascular disease, chemotherapy, chronic kidney disease, diabetes, family history of heart failure, obesity, radiotherapy, sleep apnea, and smoking |
| 4 | Annual screening for heart failure in adults with diabetes mellitus |
| 5 | Measurement upon hospital admission to determine prognosis in acutely decompensated heart failure |
That's it. Five indications. If your ICD-10 code doesn't map cleanly to one of these, expect denial.
The real issue here is indication #3 and #4. They open the door to BNP billing in endocrinology, nephrology, and oncology practices — not just cardiology. Patients on chemotherapy, patients with chronic kidney disease, and patients with diabetes are now explicitly within covered territory. If you're not billing CPT 83880 in those settings already, check whether your patient population qualifies.
The policy does not specify prior authorization requirements for CPT 83880 under these indications. That said, medical necessity documentation must be airtight. Your chart needs to clearly support which of the five indications applies — before the claim goes out, not after a denial.
Aetna BNP Testing Exclusions and Non-Covered Indications
This is where CPB 0618 gets expensive if your team isn't paying attention. Aetna considers serial BNP and NT-proBNP measurements — along with BNP in a wide range of clinical contexts — experimental, investigational, or unproven.
The list is long. Here are the highest-risk exclusions for billing teams:
| # | Excluded Procedure |
|---|---|
| 1 | Monitoring therapy effectiveness in congestive heart failure — this one catches people. Clinicians order serial BNP to track CHF treatment response. Aetna won't pay for it under CPB 0618. |
| 2 | Guiding statin decisions in heart failure patients — explicitly excluded. |
| 3 | Prognosis after acute coronary syndrome — excluded. ACS is not covered, even though heart failure is. |
| 4 | Diagnosing or screening pulmonary hypertension associated with bronchopulmonary dysplasia — excluded. |
| 5 | Prediction of atrial fibrillation after cryptogenic stroke or thoracic surgery — excluded. |
| 6 | Managing chronic renal failure — excluded. Nephrology teams billing CPT 83880 for CKD management (not risk assessment for heart failure) should flag this. |
| 7 | Prediction of acute kidney injury after non-cardiac surgery — excluded. |
| 8 | Diagnosing preeclampsia or hypertensive disorders of pregnancy — excluded. |
| 9 | Diagnosing Kawasaki disease or patent ductus arteriosus — excluded. |
| 10 | Predicting short-term mortality in sepsis — excluded. Given how often BNP gets drawn in the ICU for sepsis patients, this is a high-volume denial risk. |
| 11 | Identifying stress-induced myocardial ischemia — excluded. |
| 12 | Early cardiac dysfunction in chronic fatigue syndrome or tetralogy of Fallot — excluded. |
The pattern here is clear. Aetna covers BNP when the clinical question is "does this patient have heart failure or how bad is it?" Aetna does not cover BNP when the clinical question is anything else — even when BNP is clinically relevant.
Serial measurements deserve special attention. Even for conditions that fall within covered indications, ordering serial BNP to monitor therapy effectiveness in CHF patients is explicitly excluded. That's a significant limitation that cardiology billing teams often miss.
If your hospitalists or intensivists routinely draw BNP on sepsis admissions, loop in your compliance officer. This is a high-volume, high-denial-risk scenario under this coverage policy.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Differentiating dyspnea: heart failure vs. pulmonary disease | Covered | CPT 83880 | Document clinical presentation clearly |
| Prognosis / disease severity in chronic heart failure | Covered | CPT 83880 | Single measurement; serial monitoring is NOT covered |
| Heart failure risk in patients with risk factors (chemo, CKD, DM, obesity, smoking, etc.) | Covered | CPT 83880 | ICD-10 must reflect qualifying risk factor |
| Annual HF screening in adults with diabetes mellitus | Covered | CPT 83880 | ICD-10 from E08.00–E13.9 range required |
| Hospital admission prognosis in acutely decompensated HF | Covered | CPT 83880 | Inpatient setting; document admission timing |
| Serial BNP/NT-proBNP for monitoring CHF therapy | Experimental / Not Covered | CPT 83880 | High denial risk for cardiology practices |
| Prognosis after acute coronary syndrome | Experimental / Not Covered | CPT 83880 | ACS is not a covered indication |
| BNP for sepsis mortality prediction | Experimental / Not Covered | CPT 83880 | Common ICU draw — audit inpatient claims |
| Diagnosing preeclampsia / hypertensive disorders of pregnancy | Experimental / Not Covered | CPT 83880 | OB/GYN billing exposure |
| BNP for chronic renal failure management | Experimental / Not Covered | CPT 83880 | CKD risk assessment for HF is covered; CKD management is not |
| Pulmonary hypertension screening in bronchopulmonary dysplasia | Experimental / Not Covered | CPT 83880 | Pediatric/neonatal setting |
| Diagnosing Kawasaki disease | Experimental / Not Covered | CPT 83880 | Pediatric exclusion |
| Patent ductus arteriosus diagnosis | Experimental / Not Covered | CPT 83880 | Pediatric exclusion |
| BNP as cardiovascular biomarker in healthy normal subjects | Experimental / Not Covered | CPT 83880 | No covered indication for asymptomatic, low-risk patients |
| BNP for statin guidance in heart failure | Experimental / Not Covered | CPT 83880 | Even in covered HF patients |
| Atrial fibrillation prediction post-cryptogenic stroke or thoracic surgery | Experimental / Not Covered | CPT 83880 | High risk for cardiothoracic billing teams |
| BNP for subclinical brain damage or cerebral small vessel disease | Experimental / Not Covered | CPT 83880 | Neurology/hypertension context |
| Weaning outcome prediction from mechanical ventilation | Experimental / Not Covered | CPT 83880 | Pulm/critical care setting |
| Stress-induced myocardial ischemia | Experimental / Not Covered | CPT 83880 | Stress testing context |
| Prediction of cardiovascular complications after bariatric surgery | Experimental / Not Covered | CPT 83880 | Bariatric billing teams should flag |
| Sickle cell disease diastolic dysfunction (NT-proBNP) | Experimental / Not Covered | CPT 83880 | Hematology context |
| Prediction of type 2 diabetes risk | Experimental / Not Covered | CPT 83880 | Not a covered screening indication |
| Fatal outcome prediction after stroke | Experimental / Not Covered | CPT 83880 | Neurology/stroke setting |
| Short-term outcome prediction in congenital diaphragmatic hernia | Experimental / Not Covered | CPT 83880 | Neonatal setting |
Aetna BNP Testing Billing Guidelines and Action Items 2026
Here's what your billing team should do before and after the January 29, 2026 effective date.
| # | Action Item |
|---|---|
| 1 | Audit your CPT 83880 charge capture now. Pull claims from the last 90 days. Check every ICD-10 paired with 83880. If the diagnosis doesn't map to one of the five covered indications, you have a denial waiting to happen — or already happening. |
| 2 | Flag serial BNP orders in your cardiology workflow. Monitoring CHF therapy with serial BNP is the most common billing mistake under this policy. Work with your cardiology team to ensure clinical documentation supports a covered indication for each discrete order — not just a standing lab protocol. |
| 3 | Expand your 83880 billing to qualified oncology and nephrology patients. Indication #3 explicitly covers patients with chemotherapy or CKD as risk factors for heart failure. If you're not billing CPT 83880 for appropriate risk-factor evaluations in those populations, you're leaving covered reimbursement on the table. |
| 4 | Map ICD-10 codes carefully for diabetic patients. Indication #4 covers annual heart failure screening in adults with diabetes. Use ICD-10 codes from the E08.00–E13.9 range. Document that this is a screening encounter, not treatment monitoring. |
| 5 | Retrain inpatient and ICU billing teams on sepsis claims. BNP drawn on sepsis admissions is explicitly excluded under CPB 0618. This is a high-volume exposure area. Your hospitalists and intensivists need to know that BNP billing against sepsis ICD-10 codes (A40.x, A41.x ranges) will deny for Aetna members. Prognosis for sepsis mortality is on the exclusion list. |
| 6 | Review claims in OB/GYN, pediatrics, and bariatric surgery. Preeclampsia diagnosis, Kawasaki disease, patent ductus arteriosus, and post-bariatric cardiovascular prediction are all excluded. If these specialties bill 83880 against Aetna members, run a targeted denial analysis. |
| 7 | Talk to your compliance officer if your practice uses BNP broadly. If your team draws BNP routinely across multiple indications — especially in the ICU, heart failure clinic, or oncology infusion setting — get a compliance review before January 29, 2026. This policy is specific enough that pattern billing without indication-level documentation creates real risk. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for BNP Testing Under CPB 0618
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 83880 | CPT | Natriuretic peptide — covered when selection criteria are met (excludes use as cardiovascular biomarker in healthy normal subjects and for identifying individuals at risk of developing abnormal brain aging) |
Other CPT Codes Related to CPB 0618
These codes appear in the policy as related codes. They are not independently covered by this bulletin but may be relevant to associated clinical workups.
| Code | Type | Description |
|---|---|---|
| 82040 | CPT | Albumin; serum, plasma or whole blood |
| 82042 | CPT | Albumin; other source, quantitative, each specimen |
| 82043 | CPT | Albumin; urine (e.g., microalbumin), quantitative |
| 82044 | CPT | Albumin; urine (e.g., microalbumin), semiquantitative (e.g., reagent strip assay) |
| 82045 | CPT | Albumin; ischemia modified |
| 85378 | CPT | Fibrin degradation products, D-dimer; qualitative or semiquantitative |
| 85379 | CPT | Fibrin degradation products, D-dimer; quantitative |
| 85380 | CPT | Fibrin degradation products, D-dimer; ultrasensitive (e.g., for evaluation for venous thromboembolism) |
| 86359 | CPT | T cells; total count |
| 86360 | CPT | T cells; absolute CD4 and CD8 count, including ratio |
| 86361 | CPT | T cells; absolute CD4 count |
| 93306 | CPT | Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording |
| 93307 | CPT | Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording |
| 93308 | CPT | Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording |
| 93312 | CPT | Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording) |
| 93313 | CPT | Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording) |
| 93314 | CPT | Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording) |
Key ICD-10-CM Diagnosis Codes
The policy references 390 ICD-10-CM codes. Below are the primary diagnostic groupings. Your ICD-10 must map to a covered indication — the diagnosis code alone doesn't determine coverage; the clinical context does.
| Code / Range | Description | Covered Indication Context |
|---|---|---|
| E08.00–E13.9 | Diabetes mellitus | Annual HF screening; HF risk factor |
| E66.1, E66.2, E66.811, E66.812, E66.813, E66.89, E66.9 | Obesity | HF risk factor |
| F17.200–F17.219 | Nicotine dependence (smoking) | HF risk factor |
| F17.290–F17.291 | Nicotine dependence, other tobacco products | HF risk factor |
| C00.0–D49.9 | Neoplasms | Chemotherapy-related HF risk |
| D57.00–D57.819 | Sickle cell disorders | Referenced in exclusions — NT-proBNP for diastolic dysfunction NOT covered |
| A02.1, A22.7, A24.1, A26.7, A31.2, A32.7, A40.0–A40.9, A41.1–A41.9, A42.7, A54.86, B00.7, B37.7 | Sepsis (multiple organism-specific codes) | Referenced in exclusions — BNP for sepsis mortality prediction NOT covered |
| F01.50–F01.C4 | Vascular dementia | Referenced in policy context |
Get the Full Picture for CPT 83880
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.